When was Cognition Therapeutics founded?

Cognition Therapeutics was founded in 2007 and raised its 1st funding round 2 years after it was founded.

Where is Cognition Therapeutics located?

Cognition Therapeutics is headquartered in Pittsburgh, United States.

How many employees does Cognition Therapeutics have?

As of Jul 31, 2026, the latest employee count at Cognition Therapeutics is 29.

Is Cognition Therapeutics a funded company?

Cognition Therapeutics is a funded company, having raised a total of $36.1M across 29 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jul 15, 2009.

When was the latest funding round of Cognition Therapeutics?

Cognition Therapeutics' latest funding was a $***** Grant (prize money) round on Sep 27, 2022, with participation from 1 investor. Its primary sector is Neurology. In United States, the Neurology sector has seen $3.67B in funding in 2026 to date.

Where does Cognition Therapeutics rank among its competitors?

Cognition Therapeutics ranks 15th amongst 459 active competitors, of which 162 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Alchemab, which secured $34M in Jul, 2026.

Who are the top competitors of Cognition Therapeutics?

Cognition Therapeutics' top competitors include Denali Therapeutics, Fulcrum Therapeutics and Annexon. Among them, Alchemab secured the most recent funding round in July, 2026.

Cognition Therapeutics - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of small molecule drugs for neurodegenerative diseases. The company uses a proprietary screening technique to identify molecules capable of blocking toxic oligomeric proteins that cause the disease. It develops a pipeline for Alzheimer's, dementia, and Synucleinopathies.

Key Metrics

Founded Year

2007

Location

Pittsburgh, United States

Stage

Public

Total Funding

$36.1M in 29 rounds

Latest Funding Round

Grant (prize money), Sep 27, 2022, $*****

Investors

Golden Seeds & 29 more

Ranked

15^th among 459 active competitors

Employee Count

29 as on Jul 31, 2026

Similar Companies

Denali Therapeutics & 569 more

Exit Details

Public

View Cognition Therapeutics' full profile

Cognition Therapeutics is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Cognition Therapeutics, Inc CIN: 13-4365359 , United States, Active	Aug 20, 2007	-	21 (As on Dec 31, 2021)	-
COGNITION THERAPEUTICS INC CIN: 1455365 , United States, Active	Aug 20, 2007	-	25 (As on Dec 31, 2022)	-

Cognition Therapeutics got listed on Oct 08, 2021.

Click here to take a look at Cognition Therapeutics's IPO in detail

Cognition Therapeutics has raised a total funding of $36.1M over 29 rounds. Its first funding round was on Jul 15, 2009. Its latest funding round was a Grant (prize money) round on Sep 27, 2022 for $*****. 1 investor participated in its latest round. Cognition Therapeutics has 30 institutional investors.

Here is the list of recent funding rounds of Cognition Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 27, 2022	4775859	Grant (prize money)	6736749	2531238	8384949	4733096
Jun 2021	2711204	Grant (prize money)	4298158	9860632	7944278	Richard King Mellon Foundation
May 15, 2021	8460522	Grant (prize money)	1186289	3987770	5737467	HHS

Access funding benchmarks and valuations. Sign up today!

View details of Cognition Therapeutics's funding rounds and investors

The founders of Cognition Therapeutics are Susan Catalano and Gilbert Rishton.

Here are the details of Cognition Therapeutics' key team members:

Susan Catalano: Founder of Cognition Therapeutics.
Gilbert Rishton: Co-founder of Cognition Therapeutics.

View details of Cognition Therapeutics's Founder profiles and Board Members

Cognition Therapeutics' employee count trend

Cognition Therapeutics has 29 employees as of Jul 26. Here is Cognition Therapeutics's employee count trend over the years:

Employee count trend for Cognition Therapeutics

Uncover Cognition Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Cognition Therapeutics include Denali Therapeutics, Fulcrum Therapeutics and Annexon. Here is the list of Top 10 competitors of Cognition Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Denali Therapeutics 2015, San Francisco (United States), Public	Developer of therapies to treat neurodegenerative diseases	$347M	Foresite Capital, Baillie Gifford & 10 others	72/100
2nd	Fulcrum Therapeutics 2015, Cambridge (United States), Public	Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases	$115M	Foresite Capital, Google Ventures & 15 others	70/100
3rd	Annexon 2011, San Francisco (United States), Public	Developer of antibodies to treat complement-mediated neurodegenerative diseases	$256M	Redmile Group, Bain Capital & 17 others	67/100
4th	Regenxbio 2008, Rockville (United States), Public	Developer of AAV Gene Therapy for rare genetic diseases	$108M	Brookside Capital, Venrock & 15 others	67/100
5th	Alector 2013, San Francisco (United States), Public	Developing immuno-modulatory therapies for dementia and other neurodegenerative disorders	$215M	AbbVie, The Dementia Discovery Fund & 20 others	65/100
6th	MeiraGTx 2015, New York City (United States), Public	Developer of gene therapies for ocular and neurodegenerative diseases	-	Perceptive Advisors, Orbimed & 6 others	65/100
7th	Alchemab 2019, London (United Kingdom), Series A	Developer of antibody therapeutics for treating oncology and neurodegenerative conditions	$149M	RA Capital Management, SV Health Investors ... & 14 others	65/100
8th	Mission Therapeutics 2011, Cambridge (United Kingdom), Series D	Developer of small molecule inhibitors targeting specific disease associated enzymes	$192M	Sofinnova Partners, Pfizer Venture Investments ... & 46 others	64/100
9th	D&D Pharmatech 2014, Seongnam-si (South Korea), Public	Developer of GLP-1-based therapeutics for metabolic disease treatment	$205M	Praxis Capital, Smile Gate Investment & 10 others	64/100
10th	US World Meds 2001, Louisville (United States), Series B	Developer of therapeutics for the treatment of multiple diseases	$149M	Athyrium Capital Management, CRG & 6 others	63/100
15th	Cognition Therapeutics 2007, Pittsburgh (United States), Public	Developer of small molecule drugs for neurodegenerative diseases	$36.1M	iNetworks, Richard King Mellon Foundation ... & 28 others	60/100